Tg Therapeutics (TGTX) Common Equity (2011 - 2026)

Tg Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $583.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 145.75% year-over-year to $583.1 million; the TTM figure through Mar 2026 stood at $583.1 million (up 145.75% YoY), while the FY2025 annual figure was $648.0 million, up 191.42% from the prior year.
• Common Equity was $583.1 million for Q1 2026 at Tg Therapeutics, down from $648.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $648.0 million in Q4 2025 to a low of $27.4 million in Q1 2023.
• Historically, Common Equity has averaged $232.7 million across 5 years, with a median of $170.4 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 83.9% in 2023, then jumped 483.64% in 2024.
• A 5-year view of Common Equity shows it stood at $58.6 million in 2022, then surged by 173.95% to $160.5 million in 2023, then surged by 38.54% to $222.4 million in 2024, then soared by 191.42% to $648.0 million in 2025, then slipped by 10.01% to $583.1 million in 2026.
• The last three Common Equity figures came in at $583.1 million (Q1 2026), $648.0 million (Q4 2025), and $607.2 million (Q3 2025), per Business Quant data.